Accessibility Menu
Camurus Ab (publ) logo

Camurus Ab (publ)(OM) CAMX

Market CapSEK 35.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+894%
5 Year+195%
1 Year-19%
1 Month-6%
SEK 583.50
-2.83%
-17.00Today
Camurus Ab (publ) last closing stock price
MetricPriceDate
Last closeSEK 583.502026-08-31
Camurus Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.27%SEK 609.502026-08-24
1 month-5.51%SEK 617.502026-07-31
3 month+10.41%SEK 528.502026-06-02
Year to date-5.28%SEK 616.002025-12-30
1 year-18.96%SEK 720.002025-08-29
3 year+94.89%SEK 299.402023-09-01
5 year+195.29%SEK 197.602021-09-01
Since inception+893.78%SEK 60.432015-12-03

Camurus Ab (publ) Financials at a Glance

Market Cap

SEK 35.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 2.27B

Net Income (TTM)

SEK 678.17M

EPS (TTM)

SEK 11.32

P/E Ratio

52.77

Dividend

SEK 0.00

Beta (Volatility)

0.64 (Low)

Price

SEK 583.50

Volume

182,689

Open

SEK 599.00

Previous Close

SEK 600.50

Daily Range

SEK 583.50 - SEK 599.00

52-Week Range

SEK 430.80 - SEK 754.50

Estimated Earnings Date

Nov 5, 2026

CAMX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Camurus Ab (publ)

Camurus AB is a biopharmaceutical company focused on developing and commercializing innovative medicines for severe and chronic diseases. The company operates in multiple regions, including Europe, North America, and Asia, and is known for its advanced drug delivery technologies.

Products and Services
  • Buvidal: Buprenorphine injection for opioid dependence and chronic pain
  • Brixadi: Treatment for opioid use disorder
  • CAM2038: Innovative treatment for chronic pain and opioid use disorder
Growth Outlook
  • Revenue increased to SEK 702 million in Q2 2026, up from SEK 533 million in Q1 2026
  • Net income reached SEK 240 million in Q2 2026, reflecting strong operational performance
  • Strategic partnerships are expected to enhance product pipeline and market reach
Financial Highlights
  • Operating income margin of 41.7% in Q2 2026 indicates strong profitability
  • Cash and cash equivalents stood at SEK 4.07 billion as of June 30, 2026
  • Net income margin of 34.3% in Q2 2026 showcases effective cost management
Camurus AB has established itself as a key player in the biotechnology sector, with a robust portfolio of products aimed at addressing critical health issues. The company's innovative drug delivery systems and strategic partnerships position it well for future growth. Recent financial performance highlights a significant increase in revenue and net income, reflecting the effectiveness of its business strategies. With a strong cash position, Camurus is well-equipped to invest in further research and development, enhancing its product offerings and market presence.
AI Generated • Aug 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

301

CEO

Sven Fredrik Tiberg, PhD

Website

www.camurus.com

Headquarters

Lund, SN 224 84, SE

CAMX Financials

Key Financial Metrics (TTM)

Gross Margin

92.49%

Operating Margin

36.33%

Net Income Margin

29.92%

Return on Equity

15.54%

Return on Capital

20.37%

Return on Assets

12.78%

Earnings Yield

1.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

SEK 35.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.51M

Volume

182.69K

Avg. Volume

124.47K

Financials (TTM)

Gross Profit

SEK 2.10B

Operating Income

SEK 823.40M

EBITDA

SEK 884.72M

Operating Cash Flow

SEK 812.55M

Capital Expenditure

-SEK 157.18M

Free Cash Flow

SEK 655.37M

Cash & ST Invst.

SEK 4.07B

Total Debt

SEK 108.40M

Camurus Ab (publ) Performance Analysis

Camurus Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 956,340,00059.2%
20232023-12-31SEK 1,716,850,00079.5%
20242024-12-31SEK 1,867,581,0008.8%
20252025-12-31SEK 2,265,378,00021.3%
Camurus Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-16.1%
Q42025-12-31-18.1%
Q12026-03-3114.8%
Q22026-06-3031.7%
Camurus Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 1.01N/A
20232023-12-31SEK 7.50643.8%
20242024-12-31SEK 7.20-4.0%
20252025-12-31SEK 12.2670.3%
Camurus Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-21.8%
Q42025-12-31-47.6%
Q12026-03-3143.7%
Q22026-06-3068.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 702.08M

+3.9%

Gross Profit

SEK 657.94M

+3.7%

Gross Margin

93.71%

N/A

Market Cap

SEK 35.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

SEK 113.09M

N/A

Employees

316

N/A

Net Income

SEK 240.83M

-1.6%

EBITDA

SEK 318.23M

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 4.07B

+21.5%

Total Debt

SEK 108.40M

+4.4%

Accounts Receivable

SEK 708.66M

+0.4%

Inventory

SEK 149.68M

+20.9%

Long Term Debt

SEK 86.82M

+2.6%

Short Term Debt

SEK 21.58M

+12.3%

Return on Assets

12.78%

N/A

Return on Invested Capital

17.10%

N/A

Free Cash Flow

SEK 193.13M

-44.6%

Operating Cash Flow

SEK 234.49M

-37.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About CAMX

What is the current price of Camurus Ab (publ)?

Camurus Ab (publ) is trading at SEK 583.50 per share.

What is the 52-week range for Camurus Ab (publ)?

Over the past 52 weeks, Camurus Ab (publ) has traded between SEK 430.80 and SEK 754.50.

How much debt does Camurus Ab (publ) have?

As of the most recent reporting period, Camurus Ab (publ) reported total debt of SEK 108.40M.

How much cash does Camurus Ab (publ) have on hand?

Camurus Ab (publ) reported SEK 4.07B in cash and cash equivalents in its most recent financial results.

What is Camurus Ab (publ)’s dividend yield?

Camurus Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services